On August 18, the Food and Drug Administration (FDA) granted accelerated approval of Wegovy (semaglutide), in conjunction with a reduced-calorie diet and exercise, for people with metabolic dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis but have not yet developed cirrhosis
[1] Many patients find the thigh particularly convenient for self-administration, as it offers good visibility and accessibility
however, people who took Ozempic had more stomach-related side effects than people who took Victoza
Search strategies included the terms children/pediatric, growth hormone, growth hormone deficiency and sleep
Persistent diarrhea or constipation that lasts beyond a few weeks should always be discussed with your healthcare provider
Key Differences Summary# Strategy : CagriSema uses two proven peptides in combination